Muscarinic M1 acetylcholine receptors regulate the non-quantal release of acetylcholine in the rat neuromuscular junction via NO-dependent mechanism
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Acetylcholine metabolism MeSH
- Muscarinic Agonists pharmacology MeSH
- Muscarinic Antagonists pharmacology MeSH
- Guanylate Cyclase metabolism MeSH
- Enzyme Inhibitors pharmacology MeSH
- Calmodulin metabolism MeSH
- Rats MeSH
- Neuromuscular Junction drug effects metabolism MeSH
- Synaptic Transmission drug effects physiology MeSH
- Organ Culture Techniques MeSH
- Nitric Oxide metabolism MeSH
- Presynaptic Terminals metabolism MeSH
- Receptor, Muscarinic M1 drug effects metabolism MeSH
- Sarcoplasmic Reticulum drug effects metabolism MeSH
- Free Radical Scavengers metabolism pharmacology MeSH
- Nitric Oxide Synthase Type I antagonists & inhibitors metabolism MeSH
- Calcium Signaling drug effects physiology MeSH
- Feedback, Physiological drug effects physiology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Acetylcholine MeSH
- Muscarinic Agonists MeSH
- Muscarinic Antagonists MeSH
- Guanylate Cyclase MeSH
- Enzyme Inhibitors MeSH
- Calmodulin MeSH
- Nitric Oxide MeSH
- Receptor, Muscarinic M1 MeSH
- Free Radical Scavengers MeSH
- Nitric Oxide Synthase Type I MeSH
Nitric oxide (NO), previously demonstrated to participate in the regulation of the resting membrane potential in skeletal muscles via muscarinic receptors, also regulates non-quantal acetylcholine (ACh) secretion from rat motor nerve endings. Non-quantal ACh release was estimated by the amplitude of endplate hyperpolarization (H-effect) following a blockade of skeletal muscle post-synaptic nicotinic receptors by (+)-tubocurarine. The muscarinic agonists oxotremorine and muscarine lowered the H-effect and the M1 antagonist pirenzepine prevented this effect occurring at all. Another muscarinic agonist arecaidine but-2-ynyl ester tosylate (ABET), which is more selective for M2 receptors than for M1 receptors and 1,1-dimethyl-4-diphenylacetoxypiperidinium (DAMP), a specific antagonist of M3 cholinergic receptors had no significant effect on the H-effect. The oxotremorine-induced decrease in the H-effect was calcium and calmodulin-dependent. The decrease was negated when either NO synthase was inhibited by N(G)-nitro-L-arginine methyl ester or soluble guanylyl cyclase was inhibited by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. The target of muscle-derived NO is apparently nerve terminal guanylyl cyclase, because exogenous hemoglobin, acting as an NO scavenger, prevented the oxotremorine-induced drop in the H-effect. These results suggest that oxotremorine (and probably also non-quantal ACh) selectively inhibit the non-quantal secretion of ACh from motor nerve terminals acting on post-synaptic M1 receptors coupled to Ca(2+) channels in the sarcolemma to induce sarcoplasmic Ca(2+)-dependent synthesis and the release of NO. It seems that a substantial part of the H-effect can be physiologically regulated by this negative feedback loop, i.e., by NO from muscle fiber; there is apparently also Ca(2+)- and calmodulin-dependent regulation of ACh non-quantal release in the nerve terminal itself, as calmidazolium inhibition of the calmodulin led to a doubling of the resting H-effect.
References provided by Crossref.org
From Frog Muscle to Brain Neurons: Joys and Sorrows in Neuroscience
Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation